Navigation Links
BIO Ventures for Global Health Receives $7 Million Grant from Gates Foundation to Engage Biotechnology in the Fight Against Neglected Diseases of the Developing World
Date:10/14/2008

-Funds to support creation of market incentives and facilitate new R&D collaborations-

WASHINGTON, Oct. 14 /PRNewswire-USNewswire/ -- BIO Ventures for Global Health (BVGH) today announced that the Bill & Melinda Gates Foundation has expanded its support of the organization, so it can further engage biotechnology industry innovation to create new medicines for infectious diseases of the developing world. The $7 million grant will help BVGH build the market case for biotechnology industry investment through market-based incentives and to create new opportunities for R&D collaborations.

"We are thrilled by the Bill & Melinda Gates Foundation's support for expanding the BVGH mission," said Christopher D. Earl, PhD, President and CEO of BVGH. "Biotechnology industry resources are integral to the discovery of new solutions for the millions of patients suffering from diseases such as malaria, tuberculosis and African sleeping sickness."

Barriers such as insufficient markets, funding, and information continue to deter industry from applying their technologies to research and development for neglected tropical diseases (NTDs). BVGH is tackling these barriers and addressing the issues most often identified by both the public and private sectors as limiting collaboration and the application of biotechnology resources.

"The biotech industry has an exceptional opportunity to apply its innovative skills to create new global health solutions," said Tachi Yamada, MD, President of the Gates Foundation's Global Health Program. "BVGH designs economic incentives and partnerships that help make this industry commitment possible."

BVGH's accomplishments are measured by the growing numbers of companies who are committing their best scientists and technologies to solving the most pressing public health needs across the globe.

"Improving health care in developing nations is a goal that all biotechnology companies share," said Joshua Boger, Ph.D., President and CEO of Vertex Pharmaceuticals Incorporated, and Chairman of the Biotechnology Industry Organization (BIO). "Biotechnology innovation has dramatically changed the lives of millions of people worldwide, and our industry must remain committed to utilizing its expertise and resources to ensure that diseases of both the developed and developing world are addressed in new and more effective ways."

About Bio Ventures for Global Health

BIO Ventures for Global Health (BVGH), a non-profit organization, is harnessing the resources of the biotechnology industry to create new medicines for neglected diseases of the developing world. Our mission is to break down barriers that hinder industry involvement in global health product development and to catalyze new industry investment. http://www.bvgh.org


'/>"/>
SOURCE BIO Ventures for Global Health
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Hank Plain Joins Morgenthaler Ventures as Partner
2. Dan Broderick Joins Prolog Ventures as Partner
3. Corium International, Inc., Announces $40 Million Financing led by Essex Woodlands Health Ventures
4. Vivo Ventures Expands Team with the Addition of James Huang as an Executive in Residence
5. Khosla Ventures and BIOeCON Form KiOR Inc.
6. Jerusalem Global Ventures Announces $200 Million Growth Equity Fund
7. 5AM Ventures Announces Expansion of Investment Team: Names Richard Ulevitch Venture Partner; Promotes Kevin Forrest and Andrew McMillan to Principal
8. Clarus Ventures Closes $660 Million Fund
9. The Bill & Melinda Gates Foundation, BIO, and Bio Ventures for Global Health Invite Proteome Systems CEO to Speak on TB Diagnostics Solutions At Partnering for Global Health Forum, Washington D.C.
10. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
11. SPO Medical Retains American Capital Ventures for Investor Relations Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... YORK , June 23, 2016 ... trading session at 4,833.32, down 0.22%; the Dow Jones Industrial ... S&P 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has initiated ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ), ... Therapeutics Inc. (NASDAQ: BIND ). Learn more about ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory ... technical consulting, provides a free webinar on Performing Quality Investigations: Getting ... at 12pm CT at no charge. , Incomplete investigations are still a major ...
(Date:6/23/2016)... , June 22, 2016  Amgen (NASDAQ: ... the QB3@953 life sciences incubator to accelerate ... The shared laboratory space at QB3@953 was created to ... key obstacle for many early stage organizations - access ... the sponsorship, Amgen launched two "Amgen Golden Ticket" awards, ...
(Date:6/22/2016)... , June 22, 2016 Cell ... will allow them to produce up to one ... one lot within one week. These high-quality, consistent ... laboriously preparing cells and spend more time doing ... through a proprietary, high-volume manufacturing process that produces ...
Breaking Biology Technology:
(Date:6/21/2016)... , June 21, 2016 NuData ... the new role of principal product architect and ... the director of customer development. Both will report ... technical officer. The moves reflect NuData,s strategic growth ... response to high customer demand and customer focus ...
(Date:6/9/2016)... 2016  Perkotek an innovation leader in attendance control systems is proud to announce ... for employers to make sure the right employees are actually signing in, and to ... ... ... ...
(Date:6/2/2016)... 2, 2016 The Department of Transport ... the 44 million US Dollar project, for the , ... including Personalization, Enrolment, and IT Infrastructure , to ... production and implementation of Identity Management Solutions. Numerous renowned international ... Decatur was selected for the most compliant ...
Breaking Biology News(10 mins):